Skip to main content
Top
Published in: Acta Diabetologica 1/2016

01-02-2016 | Letter to the Editor

Chronic inflammation in offspring of patients with type 2 diabetes and albuminuria

Authors: Angela De Matthaeis, Antonia Di Lorenzo, Alessia Gargano, Gianluigi Vendemiale, Simonetta Bacci, Salvatore De Cosmo

Published in: Acta Diabetologica | Issue 1/2016

Login to get access

Excerpt

Albuminuria, a key feature of diabetic nephropathy, is one of the strongest predictors of cardiovascular events in patients with type 2 diabetes (T2DM) [1]. Moreover, it is well known the role for chronic inflammation (CI) as underlying pathogenic mechanism of atherosclerosis in non-diabetic and diabetic subjects. Recent evidences show that CI is also as a potential mediator between albuminuria and macrovascular disease [2]. Fibrinogen and C-reactive protein (CRP), both markers of inflammatory response, are consistently associated with the future cardiovascular events also in apparently healthy individuals [3]. …
Literature
1.
go back to reference Mattock MB, Morrish NJ, Viberti GC et al (1992) Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:735–741CrossRef Mattock MB, Morrish NJ, Viberti GC et al (1992) Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 41:735–741CrossRef
2.
go back to reference Festa A, D’Agostino R Jr, Howard G et al (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Intern. 58:1703–1710CrossRef Festa A, D’Agostino R Jr, Howard G et al (2000) Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the Insulin Resistance Atherosclerosis Study. Kidney Intern. 58:1703–1710CrossRef
3.
go back to reference Collaboration Emerging Risk Factors, Kaptoge S, Di Angelantonio E, Pennells L et al (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320CrossRef Collaboration Emerging Risk Factors, Kaptoge S, Di Angelantonio E, Pennells L et al (2012) C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 367:1310–1320CrossRef
4.
go back to reference Ruotsalainen E, Salmenniemi U, Vauhkonen I et al (2006) Changes in inflammatory citokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 29:2714–2720CrossRefPubMed Ruotsalainen E, Salmenniemi U, Vauhkonen I et al (2006) Changes in inflammatory citokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 29:2714–2720CrossRefPubMed
5.
go back to reference Tesauro M, Rizza S, Iantorno M et al (2007) Vascular, metabolic and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus. Metabolism 56:413–419CrossRefPubMed Tesauro M, Rizza S, Iantorno M et al (2007) Vascular, metabolic and inflammatory abnormalities in normoglycemic offspring of patients with type 2 diabetes mellitus. Metabolism 56:413–419CrossRefPubMed
Metadata
Title
Chronic inflammation in offspring of patients with type 2 diabetes and albuminuria
Authors
Angela De Matthaeis
Antonia Di Lorenzo
Alessia Gargano
Gianluigi Vendemiale
Simonetta Bacci
Salvatore De Cosmo
Publication date
01-02-2016
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-015-0747-7

Other articles of this Issue 1/2016

Acta Diabetologica 1/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.